Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT04559815
- Locations
- 🇨🇦
Master Centre for Canada, Mississauga, Ontario, Canada
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2Peripheral Arterial Disease
- Interventions
- Drug: Placebo (semaglutide)
- First Posted Date
- 2020-09-23
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 792
- Registration Number
- NCT04560998
- Locations
- 🇨🇳
The First Affiliated Hospital of Xi'an Jiaotong University-Cardiovascular, Xi'an, Shaanxi, China
🇨🇳Tianjin Union Medical Center-Cardiology, Tianjin, China
🇺🇸Angel City Research, Inc., Los Angeles, California, United States
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 194
- Registration Number
- NCT04537624
- Locations
- 🇨🇭
Master Centre Switzerland, Zurich, Oerlikon, Switzerland
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Denmark, as Part of Local Clinical Practice
- First Posted Date
- 2020-09-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 99
- Registration Number
- NCT04537637
- Locations
- 🇩🇰
Novo Nordisk investigational site, Søborg, Denmark
🇩🇰Master Centre for Denmark, Copenhagen S, Denmark
Research Study Comparing New Tablets of Semaglutide in New Doses, in Healthy People
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 290
- Registration Number
- NCT04524832
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany
A Clinical Trial Comparing Semaglutide in Healthy People Who Eat and Take the Medicine at Different Times
- First Posted Date
- 2020-08-14
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 156
- Registration Number
- NCT04513704
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Harrow, United Kingdom
Injection Site Pain Comparison of Excipient Solutions
Phase 1
Completed
- Conditions
- Obesity
- Interventions
- Other: Trial product 1Other: Trial product 2Other: Trial product 3Other: Trial product 4Other: Trial product 5Other: Trial product 6Other: Trial product 7Other: Trial product 8Other: Trial product 9Other: Trial product 10Other: Trial product 12
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2021-10-19
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 108
- Registration Number
- NCT04482725
- Locations
- 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands
Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2023-11-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3000
- Registration Number
- NCT04469855
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Yokohama, Kanagawa, Japan
A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2020-07-08
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 984
- Registration Number
- NCT04460885
- Locations
- 🇷🇺
Medinet LLC, Saint-Petersburg, Russian Federation
🇺🇸Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸Texas Diab & Endo, P.A., Round Rock, Texas, United States
Clinical Outcomes of NovoSeven® Treatment in Severe Postpartum Haemorrhage - a Study at the University Hospital of Bern
Completed
- Conditions
- Severe Postpartum Haemorrhage
- Interventions
- Other: Standard of care
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 225
- Registration Number
- NCT04444856
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Bern, Switzerland
© Copyright 2025. All Rights Reserved by MedPath